Windward prices $175M IPO to advance China-licensed lung drugs BioPharma Dive
Windward prices $175M IPO to advance China-licensed lung drugs

Windward prices $175M IPO to advance China-licensed lung drugs BioPharma Dive
Key Takeaways
- Windward prices $175M IPO to advance China-licensed lung drugs.
- Windward prices $175M IPO to advance China-licensed lung drugs BioPharma Dive Windward prices $175M IPO to advance China-licensed lung drugs BioPharma Dive
Read Complete Original Article
Published originally on BioPharma Dive





